BRIDGEBIO PHARMA LLC enters BRIDGEBIO ONCOLOGY THERAPEUTICS, INC. with 13.81M shares plus derivative instruments
Holding both equity and derivatives at entry signals strong long-term conviction in the company.
Direct Derivatives
Filed: 8/18/2025ACC: 0000950170-25-109842
10% Owner
Since Aug 2025
13.81M
Baseline shares
100% direct
13.81M
Direct ownership
1 position
73.43K
Derivative underlying
2 instruments
1
Security positions
All direct
Non-Derivative Holdings1
Common Stock
DirectShares owned13.81M
Total
13.81M direct13.81M
| Security Title | Shares Owned | Ownership Type |
|---|---|---|
| Common Stock | 13.81M | Direct |
| Total | 13.81M | 13.81M direct |
Derivative Holdings2
Stock Option (Right to Buy)
DirectUnderlying security
Common Stock
Underlying shares
9.49K
Shares owned
N/A
Exercise price
1.02
Expiration
—
Exercise window
—
Stock Option (Right to Buy)
DirectUnderlying security
Common Stock
Underlying shares
63.93K
Shares owned
N/A
Exercise price
3.83
Expiration
—
Exercise window
—
Total
Underlying
73.43K
Owned
0.00
| Security | Underlying | Exercise Price | Exercise Window | Expiration | Underlying Shares | Shares Owned |
|---|---|---|---|---|---|---|
| Stock Option (Right to Buy) Direct | Common Stock | 1.02 | — | — | 9.49K | N/A |
| Stock Option (Right to Buy) Direct | Common Stock | 3.83 | — | — | 63.93K | N/A |
| Total | 73.43K | 0.00 | ||||